These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31111305)

  • 21. In Situ Gel Formulation for Enhanced Ocular Delivery of Nepafenac.
    Shelley H; Rodriguez-Galarza RM; Duran SH; Abarca EM; Babu RJ
    J Pharm Sci; 2018 Dec; 107(12):3089-3097. PubMed ID: 30170009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of hydroxypropyl-β-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel.
    Kesavan K; Kant S; Singh PN; Pandit JK
    Curr Eye Res; 2011 Oct; 36(10):918-29. PubMed ID: 21950697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
    Loftsson T; Hreinsdóttir D; Stefánsson E
    J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development.
    Gukasyan HJ; Hailu S; Karami TK; Graham R
    Drug Discov Today; 2019 Aug; 24(8):1587-1597. PubMed ID: 30959112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
    Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use.
    Asasutjarit R; Theerachayanan T; Kewsuwan P; Veeranodha S; Fuongfuchat A; Ritthidej GC
    AAPS PharmSciTech; 2015 Oct; 16(5):1013-24. PubMed ID: 25609376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview.
    Almeida H; Amaral MH; Lobão P; Sousa Lobo JM
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1223-37. PubMed ID: 23688342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based ocular pharmacokinetic modeling using computational methods.
    Missel PJ; Sarangapani R
    Drug Discov Today; 2019 Aug; 24(8):1551-1563. PubMed ID: 31319151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Nanoparticle-Based Ophthalmic Formulation of Dexamethasone Enhances Corneal Permeability of the Drug and Prolongs Its Corneal Residence Time.
    Nagai N; Nakazawa Y; Ito Y; Kanai K; Okamoto N; Shimomura Y
    Biol Pharm Bull; 2017; 40(7):1055-1062. PubMed ID: 28674248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and evaluation of a timolol maleate drug-resin ophthalmic suspension as a sustained-release formulation in vitro and in vivo.
    Qin F; Zeng L; Zhu Y; Cao J; Wang X; Liu W
    Drug Dev Ind Pharm; 2016; 42(4):535-45. PubMed ID: 26368660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid.
    Vooturi S; Bourne D; Panda JJ; Choi S; Kim H; Yandrapu SK; Kompella UB
    J Ocul Pharmacol Ther; 2020; 36(6):404-409. PubMed ID: 32678687
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of viscosity on tear drainage and ocular residence time.
    Zhu H; Chauhan A
    Optom Vis Sci; 2008 Aug; 85(8):715-25. PubMed ID: 18677227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of ocular and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits.
    Patane MA; Schubert W; Sanford T; Gee R; Burgos M; Isom WP; Ruiz-Perez B
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):760-9. PubMed ID: 23844757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ways to improve ocular bioavailability for topical applications].
    Sirbat D; Marchal-Heussler L; Hoffman M; Maincent P
    J Fr Ophtalmol; 2000 May; 23(5):505-9; quiz 523. PubMed ID: 10844314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits.
    Lee VH; Robinson JR
    J Pharm Sci; 1979 Jun; 68(6):673-84. PubMed ID: 458563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate.
    Usayapant A; Karara AH; Narurkar MM
    Pharm Res; 1991 Dec; 8(12):1495-9. PubMed ID: 1808612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation, in vitro dissolution, and ocular bioavailability of high- and low-melting phenylephrine oxazolidines.
    Qiu Y; Guillory JK; Schoenwald RD
    Pharm Res; 1993 Nov; 10(11):1627-31. PubMed ID: 8290476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone.
    Bary AR; Tucker IG; Davies NM
    Eur J Pharm Biopharm; 2000 Sep; 50(2):237-44. PubMed ID: 10962233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs.
    Bu HZ; Gukasyan HJ; Goulet L; Lou XJ; Xiang C; Koudriakova T
    Curr Drug Metab; 2007 Feb; 8(2):91-107. PubMed ID: 17305490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.